BCAL Diagnostics Ltd (ASX:BDX) executive chair Jayne Shaw sits down with Proactive's Tylah Tully live from the ASX Small and Mid Cap Conference in September 2024.
BCAL is dedicated to achieving early and accurate diagnoses of breast cancer, with a primary focus on facilitating early intervention, ultimately leading to improved outcomes for women.
For more than a decade, BCAL has been developing non-invasive technologies to assist clinicians in the detection of breast cancer.
The cutting-edge technology was initially designed to complement existing imaging technologies such as the mammogram, but is now primed to evolve into a comprehensive monitoring and screening tool accessible to women of all ages and backgrounds, regardless of location.